EPRX · Eupraxia Pharmaceuticals Inc.
Market Cap
$427.49M
Shares
66.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.34
Open$6.46
Day$6.33–6.53
52W close$5.27–9.07
Avg vol 30d394K
Short int6.3M · 9.6% float · 28.8d
Short vol69%
DataApr 2024–Sep 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−4%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
28%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−18%
trailing
YTD return
−16%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+24% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.59% of float · ▲ +4.9% MoM · 28.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
68 holders — near 2-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
28%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+24% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.59% of float · ▲ +4.9% MoM · 28.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
68 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $6 · 28%
Range high $9
vs 200-day avg -11%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EPRX
this stock
Eupraxia Pharmaceuticals Inc.
|
$427.49M | -16.0% | — | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EPRX | -14.6% | -2.8% | -17.6% | -1.9% | -16.0% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -14.0% | -1.5% | -30.2% | -1.2% | -27.7% |
Key facts
CIK
1581178
CUSIP
29842P105
13F (30d)
68 filings
66 filers
Visit website
Investor relations